Abstract
The classification of immune-mediated demyelinating polyneuropathies has become more complex in recent years. Initial definitions of chronic inflammatory demyelinating polyneuropathy (CIDP) were often broad enough to include almost any acquired polyneuropathy with demyelinating features. However, subdivision of acquired demyelinating polyneuropathies into different categories seems justified because 1) several distinct clinical syndromes have been identified, 2) characteristic and distinctive patterns of serum antibody binding are associated with each specific clinical syndrome and, 3) the syndromes respond differently to immune modulating treatments (Table 1). Larger series and controlled trials will be necessary to determine the therapeutic regimens that optimize the benefit:risk considerations for patients with these syndromes.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
